Brickell Biotech, Inc. (BBI): Price and Financial Metrics


Brickell Biotech, Inc. (BBI): $0.74

0.00 (0.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BBI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 504

in industry

BBI POWR Grades


  • BBI scores best on the Sentiment dimension, with a Sentiment rank ahead of 65.01% of US stocks.
  • The strongest trend for BBI is in Momentum, which has been heading down over the past 48 weeks.
  • BBI ranks lowest in Momentum; there it ranks in the 5th percentile.

BBI Stock Summary

  • BBI's price/sales ratio is 186.11; that's higher than the P/S ratio of 97.73% of US stocks.
  • With a year-over-year growth in debt of -92.31%, Brickell Biotech Inc's debt growth rate surpasses just 2.43% of about US stocks.
  • As for revenue growth, note that BBI's revenue has grown -90.39% over the past 12 months; that beats the revenue growth of merely 1.39% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Brickell Biotech Inc are COCP, OMER, INS, LIFE, and SPRO.
  • Visit BBI's SEC page to see the company's official filings. To visit the company's web site, go to www.brickellbio.com.

BBI Valuation Summary

  • BBI's price/earnings ratio is -2; this is 105.48% lower than that of the median Healthcare stock.
  • Over the past 243 months, BBI's EV/EBIT ratio has gone up 17.3.
  • BBI's price/sales ratio has moved up 161 over the prior 243 months.

Below are key valuation metrics over time for BBI.

Stock Date P/S P/B P/E EV/EBIT
BBI 2021-08-31 188.4 2.8 -2.0 -1.2
BBI 2021-08-30 175.1 2.6 -1.9 -1.1
BBI 2021-08-27 178.3 2.7 -1.9 -1.1
BBI 2021-08-26 181.0 2.7 -1.9 -1.2
BBI 2021-08-25 181.0 2.7 -1.9 -1.2
BBI 2021-08-24 169.4 2.6 -1.8 -1.0

BBI Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at -15.98%.
  • The year over year cash and equivalents growth rate now stands at 388.02%.
  • Its year over year price growth rate is now at -32.54%.
BBI's revenue has moved down $12,795,000 over the prior 52 months.

The table below shows BBI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.337 -28.949 -31.845
2021-03-31 0.793 -19.315 -25.815
2020-12-31 1.822 -20.034 -20.913
2020-09-30 2.464 -29.324 -24.41
2020-06-30 3.505 -37.763 -24.947
2020-03-31 2.898 -37.419 -22.258

BBI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BBI has a Quality Grade of D, ranking ahead of 9.67% of graded US stocks.
  • BBI's asset turnover comes in at 0.011 -- ranking 386th of 677 Pharmaceutical Products stocks.
  • AMPH, VTVT, and IONS are the stocks whose asset turnover ratios are most correlated with BBI.

The table below shows BBI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.011 1 12.593
2021-03-31 0.025 1 11.420
2020-12-31 0.073 1 15.834
2020-09-30 0.116 1 40.527
2020-06-30 0.156 1 -6.335
2020-03-31 0.110 1 -1.800

BBI Price Target

For more insight on analysts targets of BBI, see our BBI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.50 Average Broker Recommendation 1.25 (Strong Buy)

BBI Stock Price Chart Interactive Chart >

Price chart for BBI

BBI Price/Volume Stats

Current price $0.74 52-week high $1.70
Prev. close $0.73 52-week low $0.47
Day low $0.72 Volume 467,480
Day high $0.75 Avg. volume 2,037,938
50-day MA $0.70 Dividend yield N/A
200-day MA $0.94 Market Cap 63.15M

Brickell Biotech, Inc. (BBI) Company Bio


Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.


BBI Latest News Stream


Event/Time News Detail
Loading, please wait...

BBI Latest Social Stream


Loading social stream, please wait...

View Full BBI Social Stream

Latest BBI News From Around the Web

Below are the latest news stories about Brickell Biotech Inc that investors may wish to consider to help them evaluate BBI as an investment opportunity.

Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and its Role in Autoimmunity

BOULDER, Colo., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (Brickell) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it is scheduled to host a key opinion leader (KOL) webinar on DYRK1A (Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1A), which is believed to play a key role in autoimmune and inflammatory diseases, on Friday, September 24, 2021 at 10:00 a.m. EDT.

Intrado Digital Media | September 17, 2021

Brickell Biotech to Participate at Upcoming September Conferences

BOULDER, Colo., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ: BBI ), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it is scheduled to participate in two upcoming virtual investment conferences, including the H.C. Wainwright 23 rd Annual Global Investment Conference, taking place September 13 15, and the Lake Street Partners 5 th Annual Best Ideas Growth Conference, taking place September 14 15. Conference Details Conference: H.C. Wainwright 23 rd Annual Global Investment Conference Presenter: Robert Brown, Brickell''s Chief Executive Officer Presentation ...

Benzinga | September 8, 2021

Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell’s clinical development strategy and medical affairs functions Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell’s clinical development strategy and medical affairs functions

Intrado Digital Media | September 1, 2021

Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022

Intrado Digital Media | September 1, 2021

Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

Dr. Luchi brings over 20 years of immunotherapeutic and drug development experience and will lead Brickell’s clinical development strategy and medical affairs functionsBOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitatin

Yahoo | September 1, 2021

Read More 'BBI' Stories Here

BBI Price Returns

1-mo 4.23%
3-mo -21.18%
6-mo -36.21%
1-year -5.13%
3-year -92.66%
5-year -96.75%
YTD -5.19%
2020 -47.97%
2019 -81.84%
2018 -35.52%
2017 -20.43%
2016 -43.90%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9563 seconds.